British Biotech 884408 - 500 Beiträge pro Seite

[Lucca]

Von einem Bekannten wurde mir letzte Woche British Biotech
als Geheimtip empfohlen. Hat jemand genauere Informationen
über diese Aktie ? Finanzen 04/2000 habe ich schon gelesen.

[Kalleman]

British Biotech ist gerade in der Endphase der Entwicklung eines Anti-Krebs-Mittels.
Erste Studien haben die Wirksamkeit bewiesen - bis zur Freigabe in den USA ist es also nicht mehr weit!

Und dann: -------------------> aufwärts.

[Graf Rotz]

mir ist bb schon vor ein paar wochen empfohlen worden (bei 0,43) mit der aussage: "das komma wird sich um eine stelle nach rechts verschieben".
ich hoffe es trifft ein!

[Brummbär]

Hi,
Lucca,

kannst du uns einen Kurzbericht über den Bericht in Finanzen geben?
Bin selber in British Biotech investiert, denke, dass mit diesem Wert über einen Zeitraum von 1 - 1,5 Jahren nichts anbrennen wird.
Sollten die vielen Tests fehlschlagen, so ist immer noch genügend Kapital (100 Mio. )in der Kasse, um geeignete Untersuchungsergebnisse zu kaufen, Bio-Firmen zu übernehmen auch eine Fusion möchte ich nicht ausschliessen.
British Biotech ist dennoch nur für spekulative Anleger geeignet, denn diese müssen sicherlich starke Nerven haben.
Meine Empfehlung: 1. Position Kaufen -> liegen lassen, eventuell 2. und 3. Paket dazukaufen -> in 1 - 1,5 J. mit viel Gewinn verkaufen!

[Lucca]

Finanzen 04/2000: GENiale Gewinne
Der Biotechnologie-Boom: 80 Aktien im Test
Seite 38: British Biotech: Hat sechs Mittel gegen verschiedene
Krebsarten in klinischen Tests. Nichts für schwache Nerven.

[MasterEd]

Sers Bio-Freaks,
schaut doch mal auf die HP!
Ich kann mich nur wiederholen:
Wer da nicht aufsteigt, muss zuschauen!!!
Von nix kommt nix!!!!
Auf jeden Fall ein paar(tausend)Stück ins Depot!
Im Mai solls soweit sein!
Dann kracht der Kurs! Entweder steil nach oben (4-5€) oder nach unten!
H O C H S P E K U L A T I V ! ! ! !

written by Bio-Ed

[02293]

Heute wurde auf N24 British Biotech von einem MWB-Mitarbeiter empfohlen.
Habe leider nur noch den Schluss mitbekommen.
Wer weis näheres dazu, vorallem zu der neuen Beteiligung ??

Gruss Knuffi

[toothstone]

Kein Verlust an der Nasdaq sollte an so einem Tag doch ein sehr gutes Zeichen sein.

[infestor2]

strong buy wg. zu erwartender kommaverschiebung!

[Schigott]

Was gibts neues von bb?????
Ist aus dem Krebsmittel was geworden???

Gruß
Der bessere Schifahrer

[bettler2099]

Es gibt wieder erfolgsversprechende News !!!!!

British Biotech in collaboration with ImmunoGen to develop and
commercialize huN901-DM1
for the treatment of small cell lung cancer

Business & Health Editors

OXFORD, England--(BUSINESS WIRE)--May 5, 2000--British Biotech and
ImmunoGen Inc. ("ImmunoGen"), a NASDAQ listed biopharmaceutical
company, have today announced that they have entered into a
collaborative agreement to develop and commercialize ImmunoGen`s
huN901-DM1, targeted at the treatment of small cell lung cancer

(SCLC).

British Biotech has been granted the exclusive rights to apply for
regulatory approval and commercialize huN901-DM1 in the EU and Japan.
ImmunoGen will retain the rights to apply for regulatory approval and
commercialize huN901-DM1 in the USA and the Rest of the World as well
as the right to manufacture the product worldwide. Upon signature of
the agreement, British Biotech paid US $1.5 million for its rights to
huN901-DM1.

Under the agreement, British Biotech and ImmunoGen will share
responsibility for the development of huN901-DM1, which is currently
in late preclinical development. ImmunoGen is responsible for
completing the preclinical development and the manufacturing and
supply of materials for clinical trials and commercial sales. British
Biotech is responsible for conducting the clinical trials necessary to
achieve regulatory approval in the USA, EU and Japan and will
reimburse ImmunoGen for the cost of clinical trial supplies. In the
event that ImmunoGen obtains regulatory approval for marketing the
product in the USA, British Biotech will receive a one-off milestone
payment. ImmunoGen will receive royalties on sales made in the EU and
Japan.

SCLC accounts for 25% of all lung cancer cases and is a
significant unmet medical need. At present, there are few treatment
options for patients who have relapsed or are refractory to
chemotherapy. Median survival for such patients is less than a year.

ImmunoGen is a leader in the development of anti-cancer agents
with high potency and reduced toxicity, through the use of its
proprietary Tumor-Activated Prodrug (TAP) technology. TAPs are
chemically-linked combinations of monoclonal antibodies and potent,

cell-killing chemicals. By virtue of the attachment of the
cell-killing chemical to the monoclonal antibody, the former is
inactive until it reaches the tumor cell to which it is targeted by

the monoclonal antibody.

huN901-DM1 is a TAP consisting of a humanized monoclonal antibody
(huN901) targeting SCLC cells, coupled with a highly potent cytotoxic
agent (DM1), a maytansine derivative. In preclinical studies,
huN901-DM1 eradicated SCLC tumors. In the same studies, cisplatin and
etoposide, drugs used in current SCLC treatment, produced only
temporary interruption of tumor growth. huN901-DM1 is in late
preclinical development; formal toxicology studies are under way and
it is anticipated that a Phase I clinical trial will start in quarter
four this year.

Dr Elliot Goldstein, Chief Executive of British Biotech,
commented, "This collaboration broadens our approach to the treatment
of cancer beyond the area of metalloenzyme inhibition. Innovative deal
terms, combined with our clinical development and regulatory
capabilities have enabled us to obtain the commercialisation rights to
a novel anti-cancer agent in Europe and Japan. We are delighted to be
working with ImmunoGen to undertake the worldwide development of
huN901-DM1."
"This innovative collaboration allows us to benefit from British
Biotech`s clinical development capabilities while retaining rights in
the US," said Mitchel Sayare, PhD, Chairman and CEO of ImmunoGen. "We
look forward to collaborating with British Biotech, one of only a few
companies who have experience in conducting clinical trials in SCLC.
We believe their unique experience in this disease, coupled with their
enthusiasm for this product, will enable us to aggressively advance
the development of huN901-DM1 to the market place."

This news release contains forward-looking statements, which reflect
the Company`s current expectation regarding future events.
Forward-looking statements involve risks and uncertainties. Actual
events could differ materially from those projected herein and depend
on a number of factors including the success of the Company`s research
strategy, the applicability of the discoveries made therein, the
successful and timely completion of clinical studies and the
uncertainties related to the regulatory process.

Notes to Editors

British Biotech is a development-stage pharmaceutical company
which is building a portfolio of products for the treatment of cancer,
infection and inflammation. These opportunities will be generated from
in-house research and development and by acquisition from, and
collaboration with, outside parties.

British Biotech currently has four products in development. Its
lead product, marimastat, a matrix metalloproteinase inhibitor, is in
Phase III development for the treatment of cancer and has been
licensed worldwide to Schering Plough Corporation except for Japan and
the Far East where it has been licensed to Tanabe Seiyaku Co., Ltd.

Further information on British Biotech is available at
www.britishbiotech.com.

ImmunoGen, a publicly traded biopharmaceutical company (NASDAQ:
IMGN) founded in 1981, develops innovative biopharmaceuticals,
primarily for cancer treatment.

ImmunoGen is a leader in developing anti-cancer agents with high
potency and reduced toxicity with its proprietary TAP technology.

By combining extremely potent drugs with monoclonal antibodies
that recognize and bind to tumor cells, ImmunoGen`s products deliver
chemotherapy directly to cancer cells. These products have the
potential to revolutionize the treatment of cancer because they are

designed to permit the use of highly toxic chemicals to eradicate
tumors without seriously impacting the health of the patient. This new
generation of chemotherapeutics also has the potential to treat
advanced or previously unresponsive forms of the disease.

The most advanced TAP, huC242-DM1/SB-408075, designed to treat
colorectal and pancreatic cancer, has been licensed to SmithKline
Beecham and is in a Phase I/II human clinical study. In addition to
its maytansinoid platform of TAPs, the Company is working on other
proprietary TAP platforms comprising agents, such as taxanes, which
exert cell-killing activity via different mechanisms of action.

Further information on ImmunoGen is available at
www.ImmunoGen.com.